PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › APG777

Drugs in development · updated 30 October 2026

APG777: clinical trials and development status

Development codeNot approved in the USNo EMA authorisation

As of 30 October 2026 APG777 is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 2 diseases. The most advanced phase is II.

4Active trials
IIMost advanced phase
2Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow APG777 and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Atopic dermatitisII3NCT07003425
AsthmaI1NCT06920901

Everything on APG777

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch